Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy ...

The treatment of ADHD in children generally involves several factors, including medication, psychotherapy, and educational interventions. Some common medications used to treat ADHD include Adderall ...

Consisting of five separate booklets, the World Drug Report 2022 provides an in-depth analysis of global drug markets and examines the nexus between drugs and the environment within the bigger picture ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the fourth quarter of 2024. Core earnings ...

Drug delivery describes the method and approach to delivering drugs or pharmaceuticals and other xenobiotics to their site of action within an organism, with the goal of achieving a therapeutic ...

This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...

Background: Multiple sclerosis is a chronic inflammatory disease of the central nervous system with a pronounced neurodegenerative component. It has been suggested that novel treatment options are ...

People receiving the drug must have received treatment for cancer in the past. Keep reading to learn about the common, mild, and serious side effects Enhertu can cause. For a general overview of ...

I am a 66-year-old white male who is active and relatively healthy. I have recently been diagnosed with prostate cancer. One ...

Novartis AG NVS, a Swiss pharma giant, is scheduled to report fourth-quarter 2024 and full-year results on Jan. 31, 2025. The ...

Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) Sales growth driven by continued st ...

Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.